Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers

Vistakon Pharmaceuticals

Status and phase: Completed; Phase 3

Conditions: Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis

Treatments: Drug: R89674 (generic name not yet established)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00223951

05-003-10

Details and patient eligibility

About

The purpose of this study is to evaluate the safety of R89674 0.25% ophthalmic solution in healthy normal volunteers

Sex: All

Ages: 3+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

healthy normal volunteers age >=3 years with normal ocular health and a best-corrected logMAR score of 0.3 or better

Exclusion criteria

intraocular surgery and/or ocular surgical intervention within last 3 months, refractive surgery within last 6 months, active ocular disorder other than refractive disorders, breastfeeding women, pregnant female < 18 years of age -

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind